Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 Mg And 5.0 Mg Bid Apixaban In Combination With Standard Therapy In Patients With Recent (less than or equal to 7 Days) Acute Coronary Syndrome (ACS).

Next Previous
X
Search
Trial Profile

A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 Mg And 5.0 Mg Bid Apixaban In Combination With Standard Therapy In Patients With Recent (less than or equal to 7 Days) Acute Coronary Syndrome (ACS).

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary)
  • Indications Acute coronary syndromes; Thrombosis
  • Focus Adverse reactions
  • Acronyms APPRAISE-J

    • Most Recent Events

    • 22 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Planned end date changed from 1 Oct 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top